As of Friday close, Harmony Biosciences Holdings Inc.’s (NASDAQ:HRMY) stock was down -$0.09, moving down -0.28 percent to $32.43. The average number of shares traded per day over the past five days has been 444,160 shares. 2 times new highs have been achieved over the past 5 days, with a $0.52 gain in that time frame. In the last twenty days, the average volume was 475,765, while in the previous 50 days, it was 469,498.
Since last month, HRMY stock retreated -7.24%. Shares of the company fell to $31.50 on 08/14/23, the lowest level in the past month. A 52-week high of $62.08 was reached on 01/03/23 after having rallying from a 52-week low of $29.81. Since the beginning of this year, HRMY’s stock price has dropped by -41.14% or -$22.67, and marked a new high 1 time. However, the stock has declined by -47.77% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
HRMY stock investors should be aware that Harmony Biosciences Holdings Inc. (HRMY) stock had its last reported insider trading activity 248 days ago on Dec 14. Nielsen Jack, the Director of the company, disposed of 2,834 shares for $59.96 on Dec 14. It resulted in a $169,927 divestment by the insider. Wicki Andreas sold 130 shares at an average price of $60.00 on Dec 14. The insider now owns 2,147,943 shares following the transaction. On Dec 13, Director Wicki Andreas sold 6,320 shares at $60.13 apiece. The transaction was valued at $380,022.
Valuation Metrics
Right now, Harmony Biosciences Holdings Inc. (HRMY) has a P/E ratio of about 9.92. The stock’s beta is 0.47. Besides these, the trailing price-to-sales (P/S) ratio of 3.92, the price-to-book (PB) ratio of 4.01, and the price-to-cash flow ratio of 12.13 may also be considered.
Financial Health
In the three months ended June 29, Harmony Biosciences Holdings Inc.’s quick ratio stood at 4.80, while its current ratio was 4.90, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.37, and the total debt-to-equity ratio was 0.39. On the profitability front, the trailing twelve-month gross margin is 80.80% percent. In the year ended June 29, EBITDA margin amounted to 32.79%, whereas operating margins totaled 29.40%. Based on annual data, HRMY earned $354.37 million in gross profit and brought in $437.86 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 33.10%. Return on equity (ROE) for the past 12 months was 47.80%.
In Harmony Biosciences Holdings Inc.’s quarter-end financial report for June 29, it reported total debt of $180.49 million against cash and short-term investments of $53.57 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. HRMY’s revenue rose 20.26% to $119.13 million during the quarter, while net income inched up to $134.22 million. While analysts expected Harmony Biosciences Holdings Inc. to report $0.63 quarterly earnings, the actual figure was $0.56 per share, beating the consensus estimate by -11.10%. During the quarter, the company generated $52.71 million in EBITDA. The liabilities of Harmony Biosciences Holdings Inc. were 275.01 million at the end of its most recent quarter ended June 29, and its total debt was $193.72 million. The value of shareholders’ equity is $60.0 million.
Technical Picture
This quick technical analysis looks at Harmony Biosciences Holdings Inc.’s (HRMY) price momentum. With a historical volatility rate of 22.60%, the RSI 9-day stood at 39.46% on 18 August.
With respect to its five-day moving average, the current Harmony Biosciences Holdings Inc. price is up by +1.63% percent or $0.52. At present, HRMY shares trade -8.93% below its 20-day simple moving average and -21.86% percent below its 100-day simple moving average. However, the stock is currently trading approximately -11.00% below its SMA50 and -37.63% below its SMA200.
Stochastic coefficient K was 14.55% and Stochastic coefficient D was 15.94%, while ATR was 1.03. Given the Stochastic reading of 14.60% for the 14-day period, the RSI (14) reading has been calculated as 40.20%. As of today, the MACD Oscillator reading stands at -0.13, while the 14-day reading stands at -0.37.
Analyst Ratings
BofA Securities launched its rating on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) to a Neutral in a note to investors on April 20, 2023. Harmony Biosciences Holdings Inc. (HRMY) has been rated Overweight by analysts. According to 0 brokerage firms, HRMY is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Harmony Biosciences Holdings Inc. stock as buy, with 5 recommending it as overweight.
With a median target price of $62.00, the current consensus forecast for the stock is $38.00 – $72.00. Based on these forecasts, analysts predict Harmony Biosciences Holdings Inc. (HRMY) will achieve an average price target of $58.50.
